What is the 13F Pro Quality Score for BMRN?

13F Pro ranks BIOMARIN PHARMACEUTICAL INC (BMRN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BMRN's current score at https://13fpro.ai/research/BMRN (free sign-up required for the full ranking).

Which hedge funds own the most BMRN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BMRN include BlackRock,, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BMRN as soon as new 13F filings post.

Where does 13F Pro source BMRN data?

All BIOMARIN PHARMACEUTICAL INC fundamentals and ownership data come directly from SEC EDGAR. BIOMARIN PHARMACEUTICAL INC files with the SEC under CIK 1048477. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BMRN in?

BIOMARIN PHARMACEUTICAL INC (BMRN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BMRN's revenue?

Per BIOMARIN PHARMACEUTICAL INC's latest 10-Q filed with the SEC on 2026-05-05, the biggest revenue drivers are: VOXZOGO ($219.9M, +3% YoY); VIMIZIM ($210.2M, +12% YoY); NAGLAZYME ($130.1M, +14% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/BMRN.

What are BMRN's largest expenses?

BIOMARIN PHARMACEUTICAL INC's latest 10-Q reports these as the largest expense items: Cost of sales ($195.0M, +29% YoY); Research and development ($178.8M, +13% YoY); Selling, general and administrative ($258.3M, +25% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is BMRN research updated on 13F Pro?

BMRN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOMARIN PHARMACEUTICAL INC(BMRN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1048477 BMRN stock profile & AI dashboard →

13F Pro Quality Score

74.1/100

Rank #167 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

72.1/100

Profitability

82.7/100

Balance Sheet

77.2/100

Earnings Quality

82.9/100

Free Cash Flow

84.5/100

Institutional Flow

59.4/100

Revenue Scale

70.4/100

Dilution Risk

24.1/100

BMRN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIOMARIN PHARMACEUTICAL INC (BMRN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMRN at 74.1/100 on a 32-signal composite quality model, placing it at rank #167 of 2,879 stocks — the top 10% of the AI-ranked universe. BMRN scores in the top quartile across free cash flow (84.5), earnings quality (82.9), profitability (82.7). Shareholder dilution risk is elevated at 24.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIOMARIN PHARMACEUTICAL INC reports quarterly revenue of $766.2M, net income of $105.5M, free cash flow of $199.7M. Top institutional holders of BMRN by reported 13-F value include BlackRock,, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, based on the most recent SEC filings. BMRN trades on the Nasdaq exchange and files with the SEC under CIK 1048477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOMARIN PHARMACEUTICAL INC directly from SEC EDGAR. BIOMARIN PHARMACEUTICAL INC's 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 74.1 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BIOMARIN PHARMACEUTICAL INC

Quirks, history, and lore behind BMRN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · listed on Nasdaq · headquartered in Northern California · focused on rare genetic diseases.
2
The Numbers
Annual revenue in the range of roughly $2 billion, built almost entirely on a handful of treatments for conditions so uncommon that patient populations number in the thousands worldwide.
3
The History
Founded in the late 1990s, it carved out a niche by pursuing diseases that larger pharma companies ignored, earning multiple orphan drug designations from the FDA along the way.
4
The Secret
Its business model depends on charging extraordinarily high prices for drugs that treat tiny patient populations — a strategy that works precisely because there is often no competition and no alternative.
5
The Lore
Its flagship enzyme replacement therapy for MPS I and other lysosomal storage disorders gave families hope where doctors once had nothing to offer — making it a household name in rare disease advocacy circles.
6
The Giveaway
The maker of Naglazyme, Vimizim, and Palynziq — treatments for some of the rarest metabolic disorders on the planet — with a ticker that rhymes with "burn."

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BMRN's Business? Latest 10-Q Breakdown

AI-extracted from BIOMARIN PHARMACEUTICAL INC's 10-Q filed 2026-05-05 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

BioMarin's Q1 2026 net income fell 43% YoY to $105.5M on $766.2M revenue (+3% YoY) as gross margin compressed 5.2 points due to NAGLAZYME manufacturing charge; Amicus acquisition closed April 2026 for $4.8B.

Biggest Revenue Drivers

Total revenue: $766.2M+3% YoY

VOXZOGO$219.9M+3% YoY

Higher sales volume from new patients initiating therapy across all regions

VIMIZIM$210.2M+12% YoY

Higher sales volume due to timing of orders in countries that place large government orders, primarily Middle East and Latin America

NAGLAZYME$130.1M+14% YoY

Higher sales volume due to timing of orders in countries placing large government orders

Other Products$206.0M-7% YoY

PALYNZIQ down 4%, ALDURAZYME down 25%, ROCTAVIAN down 75%, partially offset by BRINEURA up 17% and KUVAN flat

Largest Expense Items

Cost of sales$195.0M+29% YoY

$31.0M charge associated with unsuccessful process qualification campaign to expand NAGLAZYME manufacturing capabilities

Research and development$178.8M+13% YoY

Higher spend on BMN 401, a later-stage clinical program acquired in Q3 2025

Selling, general and administrative$258.3M+25% YoY

Increased spending on global expansion of Enzyme Therapies and VOXZOGO, plus pre-close costs related to Amicus acquisition

Watch Items from the Filing

Three customers represent 15%, 11%, and 10% of Q1 2026 product revenues (36% combined); government order timing creates significant period-to-period variation.
Amicus acquisition closed April 2026 for $4.8B total equity value plus $433M debt repayment, financed with $2.8B secured term loans and $850M 2034 Notes, raising total indebtedness to ~$4.3B post-close.
DOJ subpoena received regarding sponsored testing programs for VIMIZIM and NAGLAZYME; company cooperating but unable to assure outcome of investigation.
ROCTAVIAN voluntarily withdrawn from market in Q1 2026; $240.0M restructuring charge recorded in 2025 related to inventory write-off, asset impairment, and severance.
2027 Notes of $600M outstanding due May 2027 if not converted; company will need to refinance or repay in cash alongside new $2.8B term loan obligations.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$766.2M

Net Income

Q1 2026

$105.5M

Free Cash Flow

Q1 2026

$199.7M

ROIC

Q1 2026

1.7%

D/E Ratio

Q1 2026

0.23

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.4% YoY

$2.42BFY 2023

FY20 $1.86BFY21 $1.85BFY22 $2.10BFY23 $2.42B

Net Income

+18.4% YoY

$167.6MFY 2023

FY20 $854.0MFY21 $-64.1MFY22 $141.6MFY23 $167.6M

Operating Income

+15.4% YoY

$185.8MFY 2023

FY20 $-43.4MFY21 $-82.3MFY22 $161.0MFY23 $185.8M

EPS (Diluted)

+16.0% YoY

$0.87FY 2023

FY20 $4.50FY21 $-0.35FY22 $0.75FY23 $0.87

Total Assets

+7.3% YoY

$6.84BFY 2023

FY20 $5.85BFY21 $6.00BFY22 $6.38BFY23 $6.84B

Op. Cash Flow

-9.5% YoY

$159.3MFY 2023

FY20 $85.4MFY21 $304.5MFY22 $175.9MFY23 $159.3M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2017	FY 2016
Revenue	$2.42B +15.4%	$2.10B +13.5%	$1.85B -0.8%	$1.86B +41.6%	$1.31B +17.6%	$1.12B
Net Income	$167.6M +18.4%	$141.6M +320.9%	$-64.1M -107.5%	$854.0M +829.7%	$-117.0M +81.4%	$-630.2M
Operating Income	$185.8M +15.4%	$161.0M +295.5%	$-82.3M -89.6%	$-43.4M -195.5%	$-14.7M +98.2%	$-803.4M
EPS (Diluted)	$0.87 +16.0%	$0.75 +314.3%	$-0.35 -107.8%	$4.50 +771.6%	$-0.67 +82.4%	$-3.81
Total Assets	$6.84B +7.3%	$6.38B +6.2%	$6.00B +2.7%	$5.85B +26.2%	$4.63B +15.1%	$4.02B
Operating Cash Flow	$159.3M -9.5%	$175.9M -42.2%	$304.5M +256.7%	$85.4M +1074.8%	$-8.8M +96.2%	$-227.8M

AI Insight: BMRN Financial Trends

Sharp profitability collapse in late 2025 reversed in Q1 2026, but debt emerged and revenue remains volatile.

• Net income swung from $241M profit in Q2 2025 to $31M loss in Q3 2025, then $47M loss in Q4 2025, recovering to $106M in Q1 2026.

• Operating margin deteriorated from 33.6% in Q2 2025 to negative 6.1% in Q3 2025, rebounding to 17.0% in Q1 2026.

• Revenue grew 15.6% from Q2 2025 ($825M) to Q1 2026 ($766M baseline), but Q4 2025 spike to $875M was not sustained.

⚠ Total debt of $1,430M appeared for first time in Q1 2026; equity rose only 6.2% since Q2 2025 amid operational stress.

⚠ Operating cash flow surged to $369M in Q3 2025 despite $47M operating loss — timing or one-time benefit warrant scrutiny.

AI Insight: BMRN Ratio Trends

BMRN swung from 33.6% operating margins in Q2 2025 to losses in Q3–Q4 2025, recovering only to 16.9% in Q1 2026—a structural profitability cliff.

• Operating margin collapsed to -6.0% in Q3 2025 and -5.1% in Q4 2025, erasing 39.6pp from Q2 2025's 33.6% peak.

• Q1 2026 shows partial recovery: OpMargin rebounded to 16.9%, NPM to 13.8%, and ROIC to 6.8%, but remain well below pre-loss levels.

• TTM metrics (OpMargin 9.7%, ROIC 4.1%) reflect drag from consecutive loss quarters; leverage stable at D/E 0.23.

⚠ Q3–Q4 2025 losses suggest one-time charge, restructuring, or major product/R&D setback. Root cause critical to assess Q1 2026 recovery durability.

⚠ Q1 2026 margin recovery is encouraging, but still 13pp below Q1 2025's 30% peak. Sustainability uncertain.

Get alerted when BMRN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOMARIN PHARMACEUTICAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BMRN

BlackRock, Inc.
$1.1B19,818,301 sh
DODGE & COX
$822.6M14,561,759 sh
PRIMECAP MANAGEMENT CO/CA/
$801.8M14,194,005 sh
VANGUARD CAPITAL MANAGEMENT LLC
$488.3M8,643,164 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$468.8M8,298,475 sh
AQR CAPITAL MANAGEMENT LLC
$429.3M7,676,541 sh
STATE STREET CORP
$412.1M7,295,079 sh
VIKING GLOBAL INVESTORS LP
$398.9M7,062,077 sh
CITADEL ADVISORS LLC
$254.9M4,512,634 sh
GEODE CAPITAL MANAGEMENT, LLC
$215.8M3,819,441 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	19,818,301
DODGE & COX	$822.6M	14,561,759
PRIMECAP MANAGEMENT CO/CA/	$801.8M	14,194,005
VANGUARD CAPITAL MANAGEMENT LLC	$488.3M	8,643,164
VANGUARD PORTFOLIO MANAGEMENT LLC	$468.8M	8,298,475
AQR CAPITAL MANAGEMENT LLC	$429.3M	7,676,541
STATE STREET CORP	$412.1M	7,295,079
VIKING GLOBAL INVESTORS LP	$398.9M	7,062,077
CITADEL ADVISORS LLC	$254.9M	4,512,634
GEODE CAPITAL MANAGEMENT, LLC	$215.8M	3,819,441

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BMRN on your watchlist

Track score changes the day BIOMARIN PHARMACEUTICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BMRN a good stock to buy?

13F Pro's AI-powered analysis of BIOMARIN PHARMACEUTICAL INC (BMRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BMRN are available on the BMRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BMRN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BMRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOMARIN PHARMACEUTICAL INC's investment landscape.